Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HDAC6 modulates myofibril stiffness and diastolic function of the heart
Ying-Hsi Lin, … , Kathleen C. Woulfe, Timothy A. McKinsey
Ying-Hsi Lin, … , Kathleen C. Woulfe, Timothy A. McKinsey
Published May 16, 2022
Citation Information: J Clin Invest. 2022;132(10):e148333. https://doi.org/10.1172/JCI148333.
View: Text | PDF
Research Article Cardiology

HDAC6 modulates myofibril stiffness and diastolic function of the heart

  • Text
  • PDF
Abstract

Passive stiffness of the heart is determined largely by extracellular matrix and titin, which functions as a molecular spring within sarcomeres. Titin stiffening is associated with the development of diastolic dysfunction (DD), while augmented titin compliance appears to impair systolic performance in dilated cardiomyopathy. We found that myofibril stiffness was elevated in mice lacking histone deacetylase 6 (HDAC6). Cultured adult murine ventricular myocytes treated with a selective HDAC6 inhibitor also exhibited increased myofibril stiffness. Conversely, HDAC6 overexpression in cardiomyocytes led to decreased myofibril stiffness, as did ex vivo treatment of mouse, rat, and human myofibrils with recombinant HDAC6. Modulation of myofibril stiffness by HDAC6 was dependent on 282 amino acids encompassing a portion of the PEVK element of titin. HDAC6 colocalized with Z-disks, and proteomics analysis suggested that HDAC6 functions as a sarcomeric protein deacetylase. Finally, increased myofibril stiffness in HDAC6-deficient mice was associated with exacerbated DD in response to hypertension or aging. These findings define a role for a deacetylase in the control of myofibril function and myocardial passive stiffness, suggest that reversible acetylation alters titin compliance, and reveal the potential of targeting HDAC6 to manipulate the elastic properties of the heart to treat cardiac diseases.

Authors

Ying-Hsi Lin, Jennifer L. Major, Tim Liebner, Zaynab Hourani, Joshua G. Travers, Sara A. Wennersten, Korey R. Haefner, Maria A. Cavasin, Cortney E. Wilson, Mark Y. Jeong, Yu Han, Michael Gotthardt, Scott K. Ferguson, Amrut V. Ambardekar, Maggie P.Y. Lam, Chunaram Choudhary, Henk L. Granzier, Kathleen C. Woulfe, Timothy A. McKinsey

×

Figure 5

HDAC6 reverses PKC-mediated stiffening of human myofibrils.

Options: View larger image (or click on image) Download as PowerPoint
HDAC6 reverses PKC-mediated stiffening of human myofibrils.
(A) Schemati...
(A) Schematic representation of titin, with the impact of phosphorylation of the N2B and PEVK regions indicated. (B) Schematic representation of the ex vivo assay using human myofibrils and recombinant forms of PKCα and HDAC6. (C) Myofibril resting tension measurements at physiological sarcomere length (~2.19 μm). Mean + SEM is shown; *P < 0.05 vs. untreated myofibrils based on 1-way ANOVA with Tukey’s multiple-comparison test. (D) Myofibril resting tension–to–sarcomere length curves. Data are presented as mean ± SEM, fitted by third-order polynomials. Myofibrils from 3 nonfailing human hearts were each treated with vehicle, recombinant PKCα, or recombinant PKCα followed by recombinant HDAC6; 6–8 myofibrils per treatment were analyzed and averaged per heart. (E) Immunoblotting was performed with an anti–PKC substrates antibody and solubilized proteins from myofibrils treated as indicated. (F) Titin was immunoblotted with antibodies specific for phospho-S11916 (S11878 in human) and phospho-S12037 (S12022 in human) in the PEVK domain, as well as an antibody against the titin Z1Z2 element to assess total titin levels.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts